Your Health, We Care
February 13, 2015: The U.S. Food and Drug Administration (FDA) approved Lenvatinib for the treatment of differentiated thyroid cancer (DTC).
May 13, 2016: The U.S. Food and Drug Administration (FDA) approved Lenvatinib for the treatment of advanced renal cell carcinoma (RCC).
August 16, 2018: The U.S. Food and Drug Administration (FDA) approved Lenvatinib for first-line treatment of unresectable hepatocellular carcinoma (HCC).
September 17, 2019: The U.S. Food and Drug Administration (FDA) approved the combination of Keytruda (Pembrolizumab) and Lenvatinib for the treatment of certain types of endometrial carcinoma.
July 22, 2021: The U.S. Food and Drug Administration (FDA) approved the combination of Keytruda (Pembrolizumab) and Lenvatinib for the treatment of certain types of advanced endometrial carcinoma.
August 11, 2021: The U.S. Food and Drug Administration (FDA) approved the combination of Keytruda (Pembrolizumab) and Lenvatinib for first-line treatment of adult patients with advanced renal cell carcinoma (RCC).
On July 22, 2021, Merck & Co., Inc. and Eisai Co., Ltd. jointly announced that the U.S. Food and···【more】
Recommended：432026-05-01
Merck & Co., Inc. and Eisai Co., Ltd. jointly announced today that the U.S. Food and Drug Admini···【more】
Recommended：392026-05-01
On July 22, 2021, Merck & Co., Inc. and Eisai Co., Ltd. jointly announced that the U.S. Food and Drug Administration (FDA) had approved Merck’s anti-PD-1 therapy pembrolizumab ···【more】
Article source：Lucius LaosRelease date：2026-01-05Recommended：43
Merck & Co., Inc. and Eisai Co., Ltd. jointly announced today that the U.S. Food and Drug Administration (FDA) has approved Merck’s anti-PD-1 therapy pembrolizumab in combinati···【more】
Article source：Lucius LaosRelease date：2026-01-05Recommended：39
Lucius Pharmaceuticals (Lao) LTD. (Lucius Pharmaceuticals), with its manufacturing campus in Laos located in the capital city of Vientiane in 2020, officially begins its great journey to make effective and affordable medicines available to people in need around the world...More
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp:
